Physician profile
Ramon A Brown
NPI 1407148935
$217,118.22
in general payments reported to CMS, 2019-2025
30 companies · $17K in 2025
The $17K reported for 2025 was more than what 95% of Colon & Rectal Surgery providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $110K · 2020: $13K · 2021: $12K · 2022: $23K · 2023: $29K · 2024: $13K · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $26K · Education: $21K · Travel and Lodging: $7,539 · Food and Beverage: $3,646 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $25,900.00 |
| Education | $21,207.50 |
| Travel and Lodging | $7,538.96 |
| Food and Beverage | $3,646.17 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $250.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $184,987.86 | 2019-2025 | Da Vinci Surgical System, Da Vinci Sp |
| Ethicon INC. | $23,400.00 | 2024-2025 | |
| Baxter Healthcare | $2,646.22 | 2022-2023 | Floseal, Adept, Seprafilm |
| Evologics LLC | $2,500.00 | 2025 | |
| Ethicon Endo-Surgery INC. | $1,200.00 | 2022 | |
| Medtronic, INC. | $712.05 | 2021-2025 | Infinity Occipitocervical Upper Thoracic System, Interstim, Het |
| Prescient Surgical | $234.68 | 2019 | |
| Medtronic USA, INC. | $167.62 | 2019-2020 | |
| Stryker Corporation | $164.60 | 2023 | Spy-Phi System |
| Davol INC. | $156.39 | 2022-2024 | Phasix Mesh |
| Ethicon US, LLC | $152.37 | 2022-2025 | N/A, Vistaseal, Harmonic |
| Csl Behring | $142.79 | 2021-2024 | Kcentra |
| Tris Pharma INC | $124.99 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $73.15 | 2020-2025 | Gattex |
| Thd America, INC. | $66.27 | 2023-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tela Bio, INC. | $44.73 | 2019 | |
| Boston Scientific Corporation | $40.07 | 2023 | Spyglass |
| Trevena, INC. | $38.81 | 2021 | |
| Next Science LLC | $38.47 | 2019-2020 | |
| Dilon Technologies, INC. | $34.78 | 2024 | Hemoblast Bellows |
| Merck Sharp & Dohme LLC | $33.16 | 2019 | |
| Caris Mpi, INC. | $24.24 | 2025 | Mi Cancer Seek |
| Convatec INC. | $22.74 | 2019 | |
| Myriad Genetic Laboratories, INC. | $21.41 | 2022 | |
| Olympus America INC. | $20.10 | 2020 | |
| Biom'Up Sa | $16.94 | 2019 | |
| Smith+Nephew, INC. | $16.74 | 2024 | Pico 7 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.86 | 2019 | |
| W. L. Gore & Associates, INC. | $12.07 | 2019 | |
| Hollister Incorporated | $11.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramon Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.